Neoantigenic Bait Composition for Immune Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cancer, especially at early stages and for monitoring minimal residual disease, are limited by the inability to effectively identify cancer-specific immune cells in individuals without pathological symptoms.
Innovation Solution
A method involving a bait composition with a display moiety containing neoantigenic peptides, which binds to immune cells, allowing for the isolation and analysis of these cells, even in individuals without apparent cancer symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional medical imaging modalities (CT or MRI) are used to detect cancer, then they can visualize anatomical structures, but they cannot detect minimal residual disease (MRD) at early stages or in asymptomatic patients
Solution Approach 1:
The patent uses neoantigenic peptides displayed on particles as intermediaries to bridge the gap between immune cells and detection systems. These peptides act as mediators that specifically bind to T cell receptors on cancer-specific immune cells, enabling indirect detection of MRD through immune cell- peptide interactions rather than direct imaging of cancer cells themselves
Solution Approach 2:
The patent replaces mechanical imaging systems (CT/MRI) with a biochemical detection system based on immune cell-peptide binding. Instead of using physical imaging modalities to detect cancer, the system uses specific molecular interactions between neoantigenic peptides and T cell receptors, followed by flow cytometry or other biochemical analysis methods to detect and quantify cancer-specific immune cells
2Reliability
If screening tests are developed for early cancer detection, then prognosis can be improved, but effective screening tests do not currently exist for many cancers
Solution Approach 1:
The patent creates a universal screening platform that can be adapted to detect multiple types of cancer. By using neoantigenic peptides that can be customized for different cancer types and displaying them on standardized particles, the system provides a multi-functional solution applicable to various cancers while maintaining a consistent detection methodology
Solution Approach 2:
The patent enables adaptation to different cancers by changing the neoantigenic peptide sequence parameter. Each cancer type can be targeted by selecting or designing appropriate neoantigenic peptides specific to that cancer's mutations, allowing the same detection platform to be versatile across different cancer types through parameter customization
3Measurement precision
If neoantigenic peptides are used to bind to immune cells, then specific cancer-related immune cells can be isolated, but the complexity of the bait composition increases
Solution Approach 1:
The patent segments the detection system into distinct functional components: neoantigenic peptides for specific binding, particles for display and stabilization, and optional detectable labels for identification. This segmentation allows each component to be optimized independently while maintaining overall system simplicity and modular assembly
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the detection of cancer-specific immune cells, facilitating early cancer detection and monitoring of residual cancer post-treatment, thereby improving diagnostic accuracy and patient outcomes.
Implementation Method 1
contacting the sample with a bait composition comprising a display moiety comprising a neoantigenic peptide under a condition sufficient for an immune cell to bind to the display moiety
Data Source
AI summary
The present application provides methods of analyzing a sample of an individual exhibiting no pathological symptoms of a cancer comprising contacting the sample with a bait composition that has a display moiety having a neoantigenic peptide under a condition sufficient for an immune cell to bind to the display moiety and isolating and analyzing the immune cell. Methods of detecting a cancer (such as a residual cancer) and methods of treatments are also provided.